Upload
aliya
View
38
Download
1
Tags:
Embed Size (px)
DESCRIPTION
Keith Johnston Research Group Nanotechnology/Colloid Science [email protected] CPE 5.414 512-471-4617. Biomedical and Pharmaceutical Nanotechnology: Imaging and Therapeutics Magnetic/optical/therapeutic nanoparticles -cancer and atherosclerosis - PowerPoint PPT Presentation
Citation preview
Keith Johnston Research GroupNanotechnology/Colloid Science
[email protected] CPE 5.414 512-471-4617
Biomedical and Pharmaceutical Nanotechnology: Imaging and Therapeutics– Magnetic/optical/therapeutic nanoparticles -cancer and atherosclerosis– Protein drug delivery (oral, depot, pulmonary, parenteral)
Nanotechnology for Energy: Fundamentals and Applications
– Nanocrystal/Mesoporous composites• Supercapacitors and batteries• Catalysis- fuel cells, water oxidation
– Nanotechnology for Enhanced Oil Recovery and CO2 Sequestration• Electromagnetic imaging• Emulsions/foams for mobility control
Molec. Specific Magnetic/Optical Imaging and Therapy: Carcinogenesis and Atherosclerosis (Sokolov, Emelianov, Milner)
Portable imagingultrasound, photoacousticopt. coherence tomography Emelianov, Milner
Molecular MechanismsEarly DetectionPrognosisTreatmentMonitoring
D
Include drug payloadsAntibody, siRNA targeting
Optical properties- theory
Novel concept: build nanoclusters from nanoparticles
30 nm end-to-end
Antibodies,siRNA
Small size (20 to 50 nm): challenging to synthesize* permeation of cell membranes, leaky vasculature in cancers* prolonged circulation in bloodstream* modulate biological pathways including apoptosis
Nanoclusters of nanoparticles* pack intense and variable functionality (like viral capscids)* optical(gold), and magnetic(iron oxide) : imaging* targeting agents (Abs, siRNA)* drugs for delivery
4
Monoclonal Antibodies for Cancer, Cardiovascular and Infectious Diseases: Need for Drug Delivery
“
http://en.wikipedia.org/wiki/Image:MonoclonalAb.jpg
>20% of all biopharmaceuticals in clinical trials are mAbs
Apparent Viscosity vs. Concentration
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
0 100 200 300 400 500
concentration of Lysozyme particles (mg/mL)
Ap
pare
nt V
isco
sity (cP
)
Lysozymesuspension 1
Lysozymesuspension 2
Shire'smonoclonalantibodysolution
Therapeutic goal: 400 mg in 1 ml sub-Q injection instead of IV
Our approach: suspensions instead of solutions- min. electroviscous effects for particles instead of protein molecules
Nanoparticle-mesoporous support composites in catalysis and energy storage (Dan Slanac, Mehul Patel)
(Supercapacitors, batteries, fuel cells, water oxidation etc.)
Homogeneous Nucleation
Growth
Metal-org 1 precursor
Metal-org 2 precursor
Reduction in solvent in presence of ligands (oleic acid)
Support
Infusion
Presynthesis of bimetallic catalysts
control nanocrystal size, compostion, surface atoms
Infuse into well-ordered mesoporous materials
dispersibility
metal-support interactions
+
3-10 nm pores
Electrochemical supercapacitors for high power density and energy density (high stability vs batteries)
Adsoption of ions on surface(e.g. Li+)
(MnO2)surface + C+ + e- ↔ (MnO2-C+)surface
Surface redox reactionMnO2 + C+ + e- ↔ MnOOC
Energy Density (Wh/kg)
MnO2 nanoparticles in conformal film on mesoporous C- high surf area, rapid diffusion
16 wt% MnO2
Magnetic Nanoparticle Sensors for Oil reservoirs and CO2 sequestration
Nano size: flows freely in porous media Surface coating adjusts contact angle and adsorption at interface
Uniform size: well-structured monolayer at interface with unique rheology/elasticity
Electromagnetic field generates acoustic waves from moving interface
water
CO2
CO2
water
CO2
water
PV injected
C/Co
10-md Limestone
All injected particles eluted
Ultrasound transducerUltrasound transducer
– Bionanoparticles: Avi Murthy, Jasmine Tam [email protected] 5.432
– Protein delivery: Andrea Miller [email protected] 5.428
– Energy: Dan Slanac [email protected] 5.426, 30